Sign in

You're signed outSign in or to get full access.

Lorraine D’Alessio

Director at MANGOCEUTICALS
Board

About Lorraine D’Alessio

Lorraine D’Alessio is an independent director of Mangoceuticals, Inc. (MGRX) since October 2022, age 44 as of May 6, 2024. She is CEO and Managing Partner of D’Alessio Law Group, with legal and governance expertise, and previously served as a policy analyst for the Government of Ontario; education includes BA (University of Toronto, 2005), MPP (Queen’s University, 2006), and JD (Southwestern Law School, 2010) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Government of OntarioPolicy Analyst/Advisor2005–2007Public policy analysis experience
Artists for Change (non-profit)Board MemberSince 2016Focus on social-impact media projects

External Roles

OrganizationRoleTenureNotes
D’Alessio Law Group, PLCCEO & Managing PartnerSince 2010Immigration and entertainment law; clients include Next Models, Food Network, Pepperdine, etc.
American International Holdings Corp. (OTC: AMIH)Director; Audit Committee MemberJan 2022–Mar 2023Prior public board service

Board Governance

  • Committee assignments: Audit Committee Member; Compensation Committee Member; Chair, Nominating & Corporate Governance Committee .
  • Independence: Board determined D’Alessio is independent under Nasdaq and Exchange Act Rule 10A-3; all three committees comprise independent directors .
  • Audit Committee financial expert: Alex Hamilton designated (not D’Alessio) .
  • Board leadership: Combined Chair/CEO structure (Jacob Cohen) .
  • Attendance rate: Not disclosed.
  • Equity ownership policy: Company has no equity ownership guidelines; plans to implement an anti-hedging policy in the future (short sales discouraged) .
  • Clawback policy: Adopted Oct 26, 2023 under Nasdaq Rule 5608; applies to “Covered Officers” (executives) .

Fixed Compensation

ComponentFY 2023Notes
Annual retainer (cash)$0 No cash fees disclosed for non-executive directors in 2023
Committee chair/member feesNot disclosedNo separate fees disclosed
Meeting feesNot disclosedNo meeting fees disclosed

Performance Compensation

Grant TypeGrant DateShares/UnitsGrant Fair ValueVesting Schedule
Restricted Stock (RS)Oct 14, 202275,000$20,881 total; $0.28/share 1/3 on Oct 14, 2022; 1/3 Oct 14, 2023; 1/3 Oct 14, 2024
Unvested RS (as of Dec 31, 2023)25,000N/AFinal tranche scheduled Oct 14, 2024

Notes:

  • Non-employee director annual compensation cap under the 2022 Equity Incentive Plan: $500,000 per director ($1,000,000 in first year or for non-executive chair), measured by grant-date fair value .

Other Directorships & Interlocks

CompanyRoleTimeframeInterlock/Conflict Notes
American International Holdings Corp. (OTC: AMIH)Director; Audit Committee MemberJan 2022–Mar 2023Jacob Cohen was CEO/President of AMIH until Mar 2023 and is currently a director, indicating prior network overlap

Expertise & Qualifications

  • Legal/governance expertise: CEO/Managing Partner at D’Alessio Law Group; recognized as 2017 Leader in Law (LA Business Journal) and 2018 Enterprising Woman Award .
  • Policy and public administration: Government of Ontario experience .
  • Education: BA (International Relations), MPP, JD .
  • Board qualifications: Board cites her legal expertise and governance/controls knowledge as qualifications .

Equity Ownership

MetricAs of Dec 31, 2023As of May 6, 2024As of Feb 13, 2025
Beneficial Ownership (Common Shares)75,000 75,000 11,667
Unvested Restricted Shares25,000 25,000 Not disclosed
Shares Outstanding (for % calc)22,969,500 24,819,500 4,888,796
Ownership %0.33% (75,000/22,969,500) 0.30% (75,000/24,819,500) 0.24% (11,667/4,888,796)
Pledged/Hedged SharesNot disclosedNot disclosedNot disclosed

Notes:

  • Company executed a 1-for-15 reverse stock split effective Oct 16, 2024, which impacts share counts and historical awards .

Governance Assessment

  • Strengths:
    • Independent director with chair role on Nominating & Governance and membership on Audit and Compensation committees—positioned to influence governance standards .
    • Compensation appears equity-heavy with no cash fees in 2023, which can align director incentives with shareholder value .
  • Concerns/RED FLAGS:
    • Absence of director stock ownership guidelines and an implemented anti-hedging policy reduces alignment safeguards; company plans to implement anti-hedging but timing uncertain .
    • Significant related-party environment involving the CEO (Epiq Scripts agreements; prior AMIH ties; Mango & Peaches equity control by CEO), increasing oversight demands on independent directors and potential perception of conflicts at the issuer level .
    • Combined Chair/CEO structure concentrates power; independent oversight must be robust (no Lead Independent Director disclosed) .

Implications for investor confidence:

  • D’Alessio’s governance roles and independence are positives, but overall issuer-related party complexity and concentrated leadership elevate governance risk. Monitoring committee actions (especially Nominating/Governance and Audit) and future disclosures on hedging policies and ownership guidelines would be prudent - -.